Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials

Current Medical Research and Opinion
Peter F Buckley

Abstract

To determine the effectiveness of quetiapine (Seroquel) against specific aspects of schizophrenic symptomatology. Combined data from three placebo-controlled, double-blind, randomised trials that had previously demonstrated quetiapine's overall clinical effectiveness and tolerability were analysed. Efficacy assessments evaluated were the Clinical Global Impression (CGI) Severity of Illness score, Brief Psychiatric Rating Scale (BPRS) factors I-V, BPRS positive symptom cluster score and 18 individual BPRS items. The Simpson-Angus Scale (SAS), the Abnormal Involuntary Movements Scale (AIMS), changes in weight and prolactin concentrations and the recording of adverse events comprised the main tolerability measures. Efficacy assessments were available for a total of 426 quetiapine patients (mean age 36.9 years) with a DSM-IIIR diagnosis of schizophrenia; 502 patients were included in the tolerability analyses. The mean quetiapine dose was 300.5 mg/day with a mean maximum dose of 686.0 mg/day. Quetiapine was efficacious across a broad range of symptoms, including depression, anxiety and hostility. Significant improvements compared with placebo were noted for CGI Severity of Illness (p < 0.001) and in 14 of the 18 individual BPRS ite...Continue Reading

References

Nov 1, 1991·Statistics in Medicine·A Whitehead, J Whitehead
Nov 14, 1997·Acta Psychiatrica Scandinavica·J Peuskens, C G Link
May 15, 2001·BMJ : British Medical Journal·P Jacobsen
Sep 5, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·A Aleman, R S Kahn
Dec 18, 2001·Biological Psychiatry·P F Buckley
Feb 12, 2004·CNS Drugs·Susan M Cheer, Antona J Wagstaff

❮ Previous
Next ❯

Citations

Dec 4, 2009·Schizophrenia Bulletin·Robert W BuchananUNKNOWN Schizophrenia Patient Outcomes Research Team (PORT)
Jun 4, 2010·Journal of Clinical Psychopharmacology·Falk W LohoffKarl Rickels
Feb 28, 2008·International Clinical Psychopharmacology·Hans-Jürgen MöllerUNKNOWN Study 146 Investigators
Nov 16, 2012·Neuropsychiatric Disease and Treatment·Nizar El-Khalili
Apr 1, 2007·Neuropsychiatric Disease and Treatment·Michael RiedelHans-Jürgen Möller
Dec 31, 2010·Indian Journal of Pharmacology·Ruchita ShahNidhi Malhotra
Jun 24, 2014·Journal of Child and Adolescent Psychopharmacology·Robert L FindlingMelissa P DelBello
Jan 1, 2007·International Journal of Psychiatry in Clinical Practice·Juan Gibert For The Sos Group 1
Nov 26, 2014·Expert Opinion on Investigational Drugs·Ricardo P GarayPierre-Michel Llorca
Jul 13, 2006·Current Medical Research and Opinion·Stéphane PotvinAlain Gendron
Dec 21, 2006·Journal of Clinical Pharmacy and Therapeutics·I R De Oliveira, M F Juruena
Mar 27, 2007·Journal of Affective Disorders·Caleb M AdlerStephen M Strakowski
Dec 20, 2007·Expert Review of Neurotherapeutics·Maurizio PompiliPaolo Girardi
Jun 20, 2015·Frontiers in Endocrinology·Megan Elizabeth Rich, Heather Kingsley Caldwell
Feb 11, 2015·Experimental and Therapeutic Medicine·Márcio G Soeiro-DE-SouzaRicardo Alberto Moreno
Jan 16, 2014·The International Journal of Neuropsychopharmacology·Timm B PoepplMichael Landgrebe
Jul 3, 2013·The International Journal of Neuropsychopharmacology·Svante NybergLars Farde
Mar 9, 2017·Expert Opinion on Drug Discovery·Aline Silva de MirandaAntônio Lúcio Teixeira
Jul 28, 2007·Journal of Psychopharmacology·Beverley R TwaitesSaad A W Shakir
Oct 19, 2006·Journal of Psychopharmacology·Simon Burton
May 6, 2014·CNS Drugs·Rachel HershenbergOlga Brawman-Mintzer
Apr 29, 2020·Pharmacotherapy·Constance L ChowAmy M VandenBerg
Oct 21, 2015·CNS Drugs·Henk Temmingh, Dan J Stein
Aug 16, 2018·MedChemComm·Maria AzmanovaNicolas P E Barry
Dec 13, 2007·CNS Drugs·Anna SparshattDavid Taylor

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.